Premature Ovarian Failure Clinical Trial
Official title:
Effect of Transdermal Estradiol Replacement Therapy on Ovulation Rate in Women With Premature Ovarian Failure: A Randomized, Placebo-Controlled Trial
Verified date | December 12, 2011 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will determine whether giving estrogen replacement therapy through an estradiol
patch can improve ovulation rates in women with spontaneous premature ovarian failure. The
ovaries are glands in women that produce female hormones and normally release an egg once a
month. In women with spontaneous premature ovarian failure, the ovaries stop working too
soon. Women with this disorder have abnormally high levels of leuteinizing hormone (LH) in
their blood, which impedes normal ovulation. In some women, estrogen replacement can suppress
LH levels to the normal range.
Women between 18 and 40 years of age with premature ovarian failure may be eligible for this
4-month study. Participants receive either standard hormone replacement therapy, consisting
of an estradiol patch and progestin tablets, or placebo. The placebo group receives patches
and tablets that look the same as those for the group with active treatment but they contain
no hormone. All participants wear the patch every day and take the tablets the first 12 days
of each month. In addition to taking the study drug, participants have blood drawn once a
week for the 16 weeks of the study.
At the end of the trial, women who were in the placebo group are offered the opportunity to
receive the estrogen patch and progestin therapy for another 16 weeks and continue the blood
tests to determine if they ovulate on this treatment.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 12, 2011 |
Est. primary completion date | December 12, 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
- INCLUSION CRITERIA: Patients with karyotypically normal spontaneous premature ovarian failure (as defined by screening protocol 91-CH-0127), i.e. women who have at least 4 months of amenorrhea, two FSH levels above 40 mIU/mL, or in the menopausal range, at least one month apart, and a normal 46, XX karyotype, diagnosed with premature ovarian failure prior to the age of 40 who are between the age of 18 and 40 years will be candidates. Patients will be screened under the protocol 91-CH-0127 (Ovarian follicle function in patients with karyotypically normal spontaneous premature ovarian failure). EXCLUSION CRITERIA: 1. General smokers (greater than 2 cigarettes/d), alcohol users (greater than 2 drinks/d), body mass index (BMI, kg/m(2) greater than or equal to 30 and less than or equal to 19, major dermatologic disorders, or a history of skin sensitivity to adhesive bandages, tape or transdermal matrix patches 2. Hysterectomy 3. Medication use current and/or past use of: diuretics, anticoagulants (heparin, coumadin), glucocorticoid drugs, gonadotropin-releasing hormone agonist or antagonist therapy, chemotherapy, use of other therapies to induce ovulation such as clomiphene citrate and other assisted reproductive technologies.(At present there are no proven ways to improve ovulation rate in these women) 4. Medical history of anorexia nervosa, hyperprolactinemia, Cushing's syndrome, gastrectomy, osteogenesis imperfecta, mastocytosis, rheumatoid arthritis, long term parenteral nutrition, hemolytic anemia, hemochromatosis and thalassemia, ankylosing spondylitis, multiple myeloma, any cancer, any other major illness 5. Contraindications to hormone replacement therapy thromboembolic event associated with previous estrogen use history of endometrial cancer or hyperplasia history of breast cancer hypertriglyceridemia (fasting triglyceride levels greater than 250 mg/dL) undiagnosed vaginal bleeding known sensitivity to agents. Active liver disease with more than 3 times elevation of liver enzymes. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Kreiner D, Droesch K, Navot D, Scott R, Rosenwaks Z. Spontaneous and pharmacologically induced remissions in patients with premature ovarian failure. Obstet Gynecol. 1988 Dec;72(6):926-8. — View Citation
Santoro N, Schmidt CL. Pregnancy after an unsuccessful oocyte donation cycle. Fertil Steril. 1990 Jan;53(1):174-6. — View Citation
Wright CS, Jacobs HS. Spontaneous pregnancy in a patient with hypergonadotrophic ovarian failure. Br J Obstet Gynaecol. 1979 May;86(5):389-92. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum progesterone in the ovulatory range. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Unknown status |
NCT01853501 -
Effects of ADSC Therapy in Women With POF
|
Phase 4 | |
Completed |
NCT00417066 -
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
|
Phase 4 | |
Active, not recruiting |
NCT04675970 -
Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy
|
||
Recruiting |
NCT03480412 -
Second Step Protocol in Poor Ovarian Responder (POR)
|
||
Completed |
NCT02644447 -
Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
|
Phase 1/Phase 2 | |
Completed |
NCT03840824 -
Blood Spot Self-administered Test and Assay
|
||
Recruiting |
NCT00119925 -
'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"
|
N/A | |
Recruiting |
NCT06117982 -
The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
|
Phase 2 | |
Suspended |
NCT03816852 -
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
|
Phase 2 | |
Not yet recruiting |
NCT04390308 -
Is There A Role For Mechanical Stimulation In Ovarian Follicular Activation?
|
||
Completed |
NCT02783937 -
Filgrastim for Premature Ovarian Insufficiency
|
Phase 4 | |
Completed |
NCT00295087 -
X-Chromosome Inactivation Status and Premature Ovarian Failure
|
N/A | |
Completed |
NCT00429494 -
GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
|
Phase 2 | |
Not yet recruiting |
NCT05522634 -
A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
|
Early Phase 1 | |
Recruiting |
NCT05838157 -
The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
|
||
Withdrawn |
NCT01129947 -
The Use of DHEA in Women With Premature Ovarian Failure
|
Phase 0 | |
Completed |
NCT00001275 -
Ovarian Follicle Function in Patients With Primary Ovarian Failure
|
N/A | |
Not yet recruiting |
NCT04306185 -
Ovarian Fragmentation Study (Crespo Medical Team)
|
N/A | |
Recruiting |
NCT02062931 -
Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
|
Phase 1/Phase 2 | |
Completed |
NCT02372474 -
"It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
|
Phase 1/Phase 2 |